Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou
June 03, 2024 01:30 ET
|
Transgene S.A.
Démarrage de la sélection et de l’inclusion des patients pour la partie Phase II de cette étude internationale randomisée de Phase I/II , qui portera sur une population d’environ 80 patients au...
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
June 03, 2024 01:30 ET
|
Transgene S.A.
Patient screening and enrollment initiated for the Phase II part of the international randomized Phase I/II trial with an overall sample size of approximately 80 patients. Last patient enrollment for...
Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050
March 05, 2024 01:30 ET
|
Transgene S.A.
Strasbourg (France), Tokyo (Japon), Waltham (Mass. USA) – le 5 mars 2024, 7h30 - Transgene (Euronext Paris : TNG), une société de biotechnologie qui conçoit et développe des immunothérapies du cancer...
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
March 05, 2024 01:30 ET
|
Transgene S.A.
Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for...
Healthcare Biometric Market Size & Share to Exceed USD 20.8 Billion by 2034, at CAGR of 18.3%. “Healthcare in the Digital Age: Navigating the Booming Healthcare Biometric Market"– By PMI
February 06, 2024 21:30 ET
|
PMI
Covina, Feb. 06, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Healthcare Biometric Market size was valued at about USD 4.5 Billion in 2024 and expected to grow at CAGR of...
Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer
January 08, 2024 11:45 ET
|
Transgene S.A.
Transgene et NEC prévoient de lancer, en 2024, une extension de l’étude randomisée de Phase I en essai randomisé de phase I/II pour continuer à démontrer le potentiel de TG4050 comme traitement...
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
January 08, 2024 11:45 ET
|
Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...
Photonics Market Revenues to Reach USD 1,149.62 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
August 08, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, Aug. 08, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Photonics Market Report (2023-2028)," the market is estimated at USD 799.29 billion in 2023. It is...
Data Center Accelerator Market Revenues to Reach USD 19.20 Billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence
July 17, 2023 09:30 ET
|
Mordor Intelligence
Hyderabad, July 17, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Data Center Accelerator Market Report (2023-2028)," the market is estimated at USD 9.89 billion in...
Incident and Emergency Management Market is estimated to be US$ 229.2 billion by 2032 – By PMI
April 10, 2023 20:50 ET
|
PMI
Covina, April 10, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of Incident and Emergency Management Market accounted for US$ 121.4 billion in 2022 and is estimated to...